Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161936 | 0.90 | TSHR (0.42) | TSHRMAPTABCC4ALDH1A1GAA | |
| SCHEMBL1162364 | 0.84 | TSHR (0.42) | TSHRMAPTABCC4ALDH1A1GAA | |
| SCHEMBL8824252 | 0.81 | TSHR (0.57) | TSHRALDH1A1GAACASP1LMNA | |
| SCHEMBL8627637 | 0.81 | MAOA (0.42) | TSHRMAPTALDH1A1GAACASP1 | |
| SCHEMBL27544693 | 0.81 | TSHR (0.43) | TSHRMAPTALDH1A1GAACASP1 | |
| SCHEMBL18741294 | 0.80 | TSHR (0.60) | TSHRALDH1A1GAASMN1; SMN2EPHX2 | |
| SCHEMBL1276353 | 0.80 | TSHR (0.47) | TSHRMAPTALDH1A1GAACASP1 | |
| SCHEMBL89278 | 0.79 | TSHR (0.41) | TSHRMAPTALDH1A1GAACASP1 | |
| SCHEMBL87404 | 0.78 | TSHR (0.67) | TSHRMAPTABCC4ALDH1A1GAA | |
| SCHEMBL2824126 | 0.78 | TSHR (0.61) | TSHRMAPTABCC4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1136475-B1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | disclosed |
| US-6605723-B2 | Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst | HOFFMAN-LA ROCHE INC. | 2003-08-12 | — | — | US | disclosed |
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2001-11-01 | — | — | US | disclosed |
| EP-1136475-A1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | GRIN1, GRIN3A, GRIN2B | TSHR 1354/4885MAPT 2791/4885ABCC4 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.